NYSE · Drug Manufacturers - General

NVS (NVS) Stock

$162.46 +0.75% NYSE: NVS Healthcare

Valuation

MetricValue
Price$162.46
Market Cap$308.79B
P/E Ratio23.96
P/B Ratio7.22
P/S Ratio5.48
EPS (TTM)$7.19
52-Week High$170.46
52-Week Low$121.57
Dividend Yield3.01%

Financials & Margins

MetricValue
ROE29.64%
ROA10.34%
ROCE18.07%
Gross Margin31.15%
Operating Margin31.15%
Net Margin23.09%
Debt/Equity1.18
Current Ratio1.12

Annual Financials (USD)

Metric20212022202320242025
Revenue$44.0B$43.5B$46.7B$51.7B$54.8B
Operating Profit$10.1B$7.9B$9.8B$14.5B$17.1B
Net Profit$24.0B$7.0B$14.8B$11.9B$14.1B
EPS$10.63$3.17$7.10$5.87$7.19
Op Margin22.9%18.3%20.9%28.1%31.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$131.8B$117.5B$99.9B$102.2B$115.6B
Total Liabilities$64.0B$58.0B$53.2B$58.1B$69.0B
Cash$12.4B$7.5B$13.4B$11.5B$11.4B
Borrowings$31.0B$27.9B$26.3B$31.3B$37.0B

Latest News

Chai Discovery Announces Collaboration with Novartis to Advance AI-Driven Antibody Discovery Business Wire · Jul 13, 2026 Can AI Make Better Drugs? Not on Wall Street’s Timeline The Wall Street Journal · Jul 12, 2026 Reasons Why Investors Should Consider Betting on PTC Stock Now Zacks · Jul 10, 2026 Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? Motley Fool · Jul 9, 2026 Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight PR Newswire · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$15.1B$14.2B$14.5B$17.6B$19.2B
Investing Cash Flow$1.7B$-771.0M$2.8B$-11.3B$-6.5B
Financing Cash Flow$-3.2B$-10.5B$-5.1B$-8.5B$-9.8B
Net Cash Flow$2.7B$-4.9B$5.9B$-1.9B$-24.0M
Free Cash Flow$12.5B$12.0B$11.7B$13.8B$17.7B

Valuation & Return Ratios

MetricValue
PEG Ratio-5.33
EV / EBITDA15.50
FCF Yield5.32%
Quick Ratio0.67
Interest Coverage11.88
Return 1Y25.32%
Return 3Y65.19%
Return 5Y105.49%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABBV $261.70 +0.66% 74.06 $462.37B 2.63%
AZN $161.63 -0.52% 24.78 $250.67B 1.28%
BAYRYBayer AG $14.28 -1.11% -22.74 $56.12B 0.21%
BMY $67.66 +1.11% 14.88 $138.21B 3.73%
GILD $149.61 -0.21% -56.96 $185.75B 2.21%

About NVS

NVS is led by CEO Vasant Narasimhan, employs 75,883 people, headquartered in Basel, CH, publicly traded since 1996.

NVS stock trades at $162.46 with a market capitalization of $308.79B. The stock is valued at a price-to-earnings (P/E) ratio of 23.96, price-to-book of 7.22, price-to-sales of 5.48. Over the past 52 weeks the stock has ranged between $121.57 and $170.46, and currently trades 4.7% below its 52-week high. It pays a dividend yielding 3.01%.

On profitability, NVS generates a return on equity (ROE) of 29.64% — well above the market average, a sign of a high-quality business, return on capital employed of 18.07%, an operating margin of 31.15%, a net profit margin of 23.09%.

In its most recent fiscal year, NVS reported annual revenue of $54.8B, net profit of $14.1B, revenue has compounded at 1.9% a year over the last five years, profit at 11.7% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 1.18, a current ratio of 1.12, total assets of $115.6B, $11.4B in cash and equivalents.

NVS has a beta of 0.46 (less volatile than the overall market).

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.77 +3.66% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21% PFE Drug Manufacturers - General $29.02 +1.65%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides